The kidney and COVID-19 patients – Important considerations

Patel, Shailesh Kumar; Singh, Rohit; Rana, Jigyasa; Tiwari, Ruchi; Natesan, Senthilkumar; Harapan, Harapan; Arteaga‐Livias, Kovy; Bonilla-Aldana, D. Katterine; Rodríguez‐Morales, Alfonso J.; Dhama, Kuldeep

doi:10.1016/j.tmaid.2020.101831

Cited by 25 publications

(27 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among patients diagnosed with SARS-CoV-2, it has been reported that renal dysfunction is characterized by high levels of blood urea nitrogen, creatinine, uric acid, and D-dimer, associated with proteinuria and hematuria (90,(117)(118)(119). Recent studies have reported an incidence between 3-9% of acute kidney injury in COVID-19 patients, demonstrating renal abnormalities (94,96,111,120).…”

Section: Clinical and Radiological Changesmentioning

confidence: 99%

A 21st Century Evil: Immunopathology and New Therapies of COVID-19

et al. 2020

View full text Add to dashboard Cite

Coronavirus Disease 2019 (COVID-19) has been classified as a global threat, affecting millions of people and killing thousands. It is caused by the SARS-CoV-2 virus, which emerged at the end of 2019 in Wuhan, China, quickly spreading worldwide. COVID-19 is a disease with symptoms that range from fever and breathing difficulty to acute respiratory distress and death, critically affecting older patients and people with previous comorbidities. SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) receptor and mainly spreads through the respiratory tract, which it then uses to reach several organs. The immune system of infected patients has been demonstrated to suffer important alterations, such as lymphopenia, exhausted lymphocytes, excessive amounts of inflammatory monocytes and macrophages, especially in the lungs, and cytokine storms, which may contribute to its severity and difficulty of establishing an effective treatment. Even though no specific treatment is currently available, several studies have been investigating potential therapeutic strategies, including the use of previously approved drugs and immunotherapy. In this context, this review addresses the interaction between SARS-CoV-2 and the patient's host immune system during infection, in addition to discussing the main immunopathological mechanisms involved in the development of the disease and potential new therapeutic approaches.

show abstract

Section: Clinical and Radiological Changesmentioning

confidence: 99%

A 21st Century Evil: Immunopathology and New Therapies of COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Prior studies had shown that the incidence of acute kidney injury in COVID-19 patients was speculated to be as high as 25%( 3 ). There were also autopsy reports showing evidence of viral tropism to the renal system.…”

Section: Introductionmentioning

confidence: 99%

“…There were also autopsy reports showing evidence of viral tropism to the renal system. It was also shown that 60% of 147 patients with COVID-19 had experienced proteinuria, with 48% experiencing hematuria( 3 ). Lab values had demonstrated that patients experienced increased BUN and creatinine( 3 ) showing further evidence of renal insult.…”

Section: Introductionmentioning

confidence: 99%

“…It was also shown that 60% of 147 patients with COVID-19 had experienced proteinuria, with 48% experiencing hematuria( 3 ). Lab values had demonstrated that patients experienced increased BUN and creatinine( 3 ) showing further evidence of renal insult. Understanding the impact of COVID-19 on the renal system is tantamount as acute kidney injuries (AKI) may be associated with increase mortality, particularly for patients that require escalating treatment such as renal replacement therapy( 3 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 impact on the renal system: Pathophysiology and clinical outcomes

Kaye

Okeagu

Tortorich

et al. 2021

Best Practice & Research Clinical Anaesthesiology

View full text Add to dashboard Cite

COVID-19 has numerous deleterious effects throughout the body. Prior studies had shown that the incidence of acute kidney injury in COVID-19 patients could be as high as 25%. There are also autopsy reports showing evidence of viral tropism to the renal system. In this regard, COVID-19 can damage the kidneys and increase a patient's risk of requiring dialysis. Available evidence suggests that renal involvement in COVID-19 infection is not uncommon, and there has been an increased incidence of chronic kidney disease related to the pandemic. In this present review, we address COVID-19 and its effects on the renal system, including the pathophysiologic mechanisms. We also address current studies on the causes of injury to the renal system, the cause of kidney failure, its effect on mortality, the impact on dialysis patients, and the impact on renal transplant patients. COVID-19 disease may have unique features in individuals on chronic dialysis and kidney transplant recipients, requiring increased vigilance in limiting viral transmission in perioperative, in-patient, and dialysis center settings.

show abstract

“…There are nearly 30.9 million confirmed infected cases and 960 K death so far (information as per 21/09/2020). The virus which caused infection all across the globe was identified to be a member of the Coronavirus family and WHO declared the disease as COVID-19 (Patel et al, 2020). The international committee on taxonomy of viruses declared the novel coronavirus as 'Severe Acute Respiratory Syndrome Coronavirus-2' (SARS-CoV-2) on 11 February 2020 (Gorbalenya et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

Molecular modeling study of tectoquinone and acteoside from Tectona grandis linn: a new SARS-CoV-2 main protease inhibitor against COVID-19

Kallingal

Kundil

Ayyolath

et al. 2020

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), a highly contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has drastically changed the lifestyle of people around the globe. Due to the lack of specific and effective antiviral drugs, transmission of the disease increases exponentially and makes it more serious and harder to control. Drugs that were assumed to be effective against COVID-19 have failed in various stages of clinical trials and this made the scientific community more disappointed. But, the race of researchers for developing new and effective antiviral to stop the disease progression still continues and our work is one among them. This study is an attempt to analyze the action of Tectoquinone and Acteoside; an important phytocompound, on SARS-CoV2 viral protease via in silico approach. The compounds were selected on the basis of their molecular docking values and they were subjected to molecular dynamics simulations about 50 ns to determine the stability and the thermodynamic feasibility between the target and the ligands. Binding energies like hydrogen bonding, hydrophobic and electrostatic interactions of the complexes were determined after MD simulations. The Pharmacokinetics and drug likeness evaluation of the compounds provide a strong evidence for the use of these compounds in developing drugs for clinical trials. Thus, the current study reveals the potential phytoconstituents present in Tectona grandis Linn to inhibit COVID-19 viral protease and thereby act as a lead therapeutic agent.

show abstract

The kidney and COVID-19 patients – Important considerations

Cited by 25 publications

References 17 publications

A 21st Century Evil: Immunopathology and New Therapies of COVID-19

A 21st Century Evil: Immunopathology and New Therapies of COVID-19

COVID-19 impact on the renal system: Pathophysiology and clinical outcomes

Molecular modeling study of tectoquinone and acteoside from Tectona grandis linn: a new SARS-CoV-2 main protease inhibitor against COVID-19

Contact Info

Product

Resources

About